1Center for Breast Cancer, National Cancer Center, Goyang, Korea
2Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Science, Seoul, Korea
3Biostatistics Collaboration Team, Research Core Center, Research Institute of National Cancer Center, Goyang, Korea
4Department of Surgery, Seoul National University College of Medicine, Seoul, Korea
5Cancer Research Institute, Seoul National University, Seoul, Korea
6Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
7Cancer Healthcare Research Branch, Research Institute of National Cancer Center, Goyang, Korea
Copyright © 2023 by the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ethical Statement
This study was approved by the Institutional Review Board of the National Cancer Center (IRB number: NCC2021-0258) and conducted in accordance with the tenets of the Declaration of Helsinki. The requirement for informed consent was waived because the study was a retrospective medical record review.
Author Contributions
Conceived and designed the analysis: Lee EG, Kim EK, Jung SY, Moon HG.
Collected the data: Lee EG, Han Y, Koh HW.
Contributed data or analysis tools: Lee DE.
Performed the analysis: Lee DE.
Wrote the paper: Lee EG, Jung SY.
Writing - review and editing: Lee EG, Lee DE, Moon HG, Han Y, Ko HW, Kim EK, Jung SY.
Funding acquisition: Jung SY.
Supervision: Kim EK, Jung SY.
Conflicts of Interest
Conflict of interest relevant to this article was not reported.
Characteristic | Total (n=6,514) | Pre–COVID-19 (2019) (n=3,182) | COVID-19 (≥ 2020) (n=3,332) | p-value |
---|---|---|---|---|
Age (yr) | ||||
Mean±SD | 53.2±11.1 | 53.0±10.9 | 53.4±11.3 | 0.157a) |
Median (min-max) | 52 (20–91) | 52 (23–88) | 52 (20–91) | |
Age group (yr) | ||||
≤ 40 | 745 (11.4) | 360 (11.3) | 385 (11.6) | 0.320b) |
41–65 | 4,850 (74.5) | 2,393 (75.2) | 2,457 (73.7) | |
> 65 | 919 (14.1) | 429 (13.5) | 490 (14.7) | |
Age group (yr) | ||||
≤ 40 | 745 (11.4) | 360 (11.3) | 385 (11.6) | 0.556b) |
41–50 | 2,240 (34.4) | 1,106 (34.8) | 1,134 (34.0) | |
51–60 | 1,908 (29.3) | 941 (29.6) | 967 (29.0) | |
61–70 | 1,120 (17.2) | 548 (17.2) | 572 (17.2) | |
> 70 | 501 (7.7) | 227 (7.1) | 274 (8.2) | |
Sex | ||||
Male | 12 (0.2) | 7 (0.2) | 5 (0.1) | 0.573c) |
Female | 6,502 (99.8) | 3,175 (99.8) | 3,327 (99.9) | |
Detection of cancer | ||||
Screening | 3,452 (53.0) | 1,638 (51.5) | 1,814 (54.4) | < 0.001b) |
Symptomatic | 2,922 (44.9) | 1,490 (46.8) | 1,432 (43.0) | |
Unknown | 140 (2.1) | 54 (1.7) | 86 (2.6) | |
T category (unknown=48) | ||||
0 | 30 (0.5) | 24 (0.7) | 6 (0.2) | 0.002b) |
1 | 3,587 (55.5) | 1,703 (54.1) | 1,884 (56.8) | |
2 | 2,341 (36.2) | 1,161 (36.9) | 1,180 (35.6) | |
3 | 343 (5.3) | 173 (5.5) | 170 (5.1) | |
4 | 165 (2.5) | 88 (2.8) | 77 (2.3) | |
N category (unknown=42) | ||||
0 | 3,968 (61.3) | 1,889 (59.9) | 2,079 (62.7) | 0.071b) |
1 | 1,627 (25.1) | 821 (26.0) | 806 (24.3) | |
2 | 510 (7.9) | 259 (8.2) | 251 (7.6) | |
3 | 329 (5.1) | 172 (5.5) | 157 (4.7) | |
4 | 38 (0.6) | 14 (0.4) | 24 (0.7) | |
Stage | ||||
I | 3,041 (46.7) | 1,440 (45.2) | 1,601 (48.1) | 0.001b) |
II | 2,405 (36.9) | 1,178 (37.0) | 1,227 (36.8) | |
III | 964 (14.8) | 495 (15.6) | 469 (14.1) | |
IV | 104 (1.6) | 69 (2.2) | 35 (1.0) | |
Subtypes (unknown=60) | ||||
HR+/HER2− | 4,122 (63.9) | 2,005 (63.5) | 2,117 (64.2) | 0.452b) |
HR+/HER2+ | 636 (9.8) | 298 (9.4) | 338 (10.3) | |
HR−/HER2+ | 714 (11.1) | 358 (11.4) | 356 (10.8) | |
HR−/HER2− | 982 (15.2) | 496 (15.7) | 486 (14.7) |
Characteristic | Total (n=6,514) | Pre–COVID-19 (2019) (n=3,182) | COVID-19 (≥ 2020) (n=3,332) | p-value |
---|---|---|---|---|
Type of first treatment | ||||
Surgery | 4,820 (74.0) | 2,279 (71.6) | 2,541 (76.3) | < 0.001a) |
Chemotherapy | 1,639 (25.2) | 867 (27.3) | 772 (23.2) | |
Hormone therapy | 54 (0.8) | 36 (1.1) | 18 (0.5) | |
Radiation therapy | 1 (0.0) | 0 | 1 (0.0) | |
Surgery as first treatment (n=4,820) | ||||
Surgery type | ||||
BCS | 3,415 (70.9) | 1,561 (68.5) | 1,854 (73.0) | 0.001a) |
Mastectomy | 1,400 (29.0) | 714 (31.3) | 686 (27.0) | |
Axillary only | 5 (0.1) | 4 (0.2) | 1 (0.0) | |
Chemotherapy as first treatment (n=1,639) | ||||
Chemotherapy | ||||
Neoadjuvant | 1,592 (97.1) | 838 (96.7) | 754 (97.7) | 0.220a) |
Palliative | 47 (2.9) | 29 (3.3) | 18 (2.3) | |
Time duration from diagnosis to first treatment (day) | ||||
Median (min-max) | 36 (0–348) | 37 (0–348) | 35 (0–280) | 0.001b) |
Characteristic |
Hospital 1 |
Hospital 2 |
Hospital 3 |
||||||
---|---|---|---|---|---|---|---|---|---|
Pre–COVID-19 (2019) (n=1,399) | COVID-19 (≥ 2020) (n=1,596) | p-value | Pre–COVID-19 (2019) (n=833) | COVID-19 (≥ 2020) (n=900) | p-value | Pre–COVID-19 (2019) (n=925) | COVID-19 (≥ 2020) (n=861) | p-value | |
Age (yr) | |||||||||
Mean±SD | 52.7±10.8 | 52.7±11.1 | 0.981a) | 53.6±10.9 | 54.8±11.2 | 0.020a) | 53.0±11.1 | 53.3±11.8 | 0.649a) |
Median (min-max) | 52 (23–87) | 51 (20–86) | 52 (30–88) | 53 (29–91) | 51 (26–85) | 51 (22–89) | |||
Age group (yr) | |||||||||
≤ 40 | 169 (12.1) | 208 (13.0) | 0.652b) | 83 (10.0) | 70 (7.8) | 0.060b) | 108 (11.4) | 107 (12.8) | 0.523b) |
41–65 | 1,061 (75.8) | 1,188 (74.4) | 634 (76.1) | 674 (74.9) | 698 (73.5) | 595 (71.2) | |||
> 65 | 169 (12.1) | 200 (12.6) | 116 (13.9) | 156 (17.3) | 144 (15.1) | 134 (16.0) | |||
Age group (yr) | |||||||||
≤ 40 | 169 (12.1) | 208 (13.0) | 0.783b) | 83 (10.0) | 70 (7.8) | 0.310b) | 108 (11.4) | 107 (12.8) | 0.348b) |
41–50 | 466 (33.3) | 535 (33.5) | 294 (35.3) | 296 (32.9) | 346 (36.4) | 303 (36.2) | |||
51–60 | 435 (31.1) | 476 (29.9) | 245 (29.4) | 287 (31.9) | 261 (27.5) | 204 (24.4) | |||
61–70 | 248 (17.7) | 273 (17.1) | 139 (16.7) | 159 (17.6) | 161 (16.9) | 140 (16.8) | |||
> 70 | 81 (5.8) | 104 (6.5) | 72 (8.6) | 88 (9.8) | 74 (7.8) | 82 (9.8) | |||
Detection of cancer | |||||||||
Screening | 1,051 (75.1) | 1,213 (76.0) | 0.049c) | 184 (22.1) | 239 (26.6) | 0.031b) | 403 (42.4) | 362 (43.3) | 0.004b) |
Symptomatic | 348 (24.9) | 377 (23.6) | 649 (77.9) | 661 (73.4) | 493 (51.9) | 394 (47.1) | |||
Unknown | 0 | 6 (0.4) | 54 (5.7) | 80 (9.6) | |||||
Stage | |||||||||
I | 583 (41.7) | 703 (44.0) | 0.073b) | 378 (45.4) | 465 (51.7) | < 0.001b) | 479 (50.4) | 433 (51.8) | 0.119b) |
II | 541 (38.7) | 616 (38.6) | 288 (34.6) | 327 (36.3) | 349 (36.7) | 284 (34.0) | |||
III | 256 (18.3) | 268 (16.8) | 129 (15.5) | 86 (9.6) | 110 (11.6) | 115 (13.7) | |||
IV | 19 (1.3) | 9 (0.6) | 38 (4.5) | 22 (2.4) | 12 (1.3) | 4 (0.5) | |||
T category (unknown=46) | |||||||||
0 | 7 (0.5) | 3 (0.2) | 0.058b) | 6 (0.7) | 2 (0.2) | 0.001b) | 11 (1.2) | 1 (0.1) | 0.012b) |
1 | 686 (49.0) | 831 (52.1) | 438 (54.8) | 538 (60.8) | 579 (60.9) | 515 (61.6) | |||
2 | 565 (40.4) | 605 (37.9) | 280 (35.0) | 304 (34.4) | 316 (33.3) | 271 (32.4) | |||
3 | 72 (5.2) | 99 (6.2) | 59 (7.4) | 31 (3.5) | 42 (4.4) | 40 (4.8) | |||
4 | 69 (4.9) | 58 (3.6) | 17 (2.1) | 10 (1.1) | 2 (0.2) | 9 (1.1) | |||
N category (unknown=42) | |||||||||
0 | 824 (58.9) | 964 (60.4) | 0.521b) | 448 (55.6) | 572 (64.7) | < 0.001b) | 617 (65.0) | 543 (64.9) | 0.931b) |
1 | 346 (24.7) | 396 (24.8) | 256 (31.8) | 225 (25.4) | 219 (23.0) | 185 (22.1) | |||
2 | 151 (10.8) | 153 (9.6) | 42 (5.2) | 39 (4.4) | 66 (7.0) | 59 (7.1) | |||
3 | 77 (5.5) | 79 (5.0) | 52 (6.4) | 33 (3.7) | 43 (4.5) | 45 (5.4) | |||
4 | 1 (0.1) | 4 (0.2) | 8 (1.0) | 16 (1.8) | 5 (0.5) | 4 (0.5) | |||
Subtypes (unknown=60) | |||||||||
HR+/HER2− | 852 (62.0) | 996 (63.7) | 0.048b) | 532 (63.9) | 569 (63.4) | 0.974b) | 621 (65.4) | 552 (66.0) | 0.979b) |
HR+/HER2+ | 123 (9.0) | 174 (11.1) | 82 (9.8) | 87 (9.7) | 93 (9.8) | 77 (9.2) | |||
HR−/HER2+ | 151 (10.9) | 149 (9.6) | 96 (11.5) | 110 (12.2) | 111 (11.7) | 97 (11.6) | |||
HR−/HER2− | 248 (18.1) | 244 (15.6) | 123 (14.8) | 132 (14.7) | 125 (13.1) | 110 (13.2) | |||
Type of first treatment | |||||||||
Surgery | 1,006 (71.9) | 1,129 (70.7) | 0.654b) | 540 (64.8) | 729 (81.0) | < 0.001c) | 733 (77.2) | 683 (81.7) | 0.038c) |
Chemotherapy | 387 (27.7) | 462 (29.0) | 269 (32.3) | 159 (17.7) | 211 (22.2) | 151 (18.1) | |||
Hormone therapy | 6 (0.4) | 5 (0.3) | 24 (2.9) | 11 (1.2) | 6 (0.6) | 2 (0.2) | |||
Radiation therapy | 0 | 1 (0.1) | |||||||
Surgery as first treatment | |||||||||
Surgery type | |||||||||
BCS | 619 (61.5) | 695 (61.6) | > 0.99c) | 465 (86.1) | 642 (88.1) | 0.282c) | 477 (65.1) | 517 (75.7) | < 0.001c) |
Mastectomy | 386 (38.4) | 433 (38.3) | 74 (13.7) | 87 (11.9) | 254 (34.6) | 166 (24.3) | |||
Axillary only | 1 (0.1) | 1 (0.1) | 1 (0.2) | 0 | 2 (0.3) | 0 | |||
Chemotherapy as first treatment | |||||||||
Chemotherapy | |||||||||
Neoadjuvant | 376 (97.2) | 457 (98.9) | 0.060b) | 252 (93.7) | 147 (92.5) | 0.625b) | 210 (99.5) | 150 (99.3) | > 0.99c) |
Palliative | 11 (2.8) | 5 (1.1) | 17 (6.3) | 12 (7.5) | 1 (0.5) | 1 (0.7) | |||
Time duration from diagnosis to first treatment (day) | |||||||||
Median (min-max) | 46 (0–348) | 41 (0–280) | < 0.000d) | 37 (0–170) | 35 (0–117) | 0.013d) | 28 (0–311) | 28 (0–117) | 0.866d) |
Values are presented as number (%) unless otherwise indicated. BCS, breast conserving surgery; COVID-19, coronavirus disease 2019; HER2, human epidermal growth factor receptor 2; HR, hormonal receptor; N, node; SD, standard deviation; T, tumor.
a) t test,
b) Chi-squared test,
c) Fisher’s exact test,
d) Wilcoxon rank sum test.
Characteristic | Total (n=6,514) | Pre–COVID-19 (2019) (n=3,182) | COVID-19 (≥ 2020) (n=3,332) | p-value |
---|---|---|---|---|
Age (yr) | ||||
Mean±SD | 53.2±11.1 | 53.0±10.9 | 53.4±11.3 | 0.157 |
Median (min-max) | 52 (20–91) | 52 (23–88) | 52 (20–91) | |
Age group (yr) | ||||
≤ 40 | 745 (11.4) | 360 (11.3) | 385 (11.6) | 0.320 |
41–65 | 4,850 (74.5) | 2,393 (75.2) | 2,457 (73.7) | |
> 65 | 919 (14.1) | 429 (13.5) | 490 (14.7) | |
Age group (yr) | ||||
≤ 40 | 745 (11.4) | 360 (11.3) | 385 (11.6) | 0.556 |
41–50 | 2,240 (34.4) | 1,106 (34.8) | 1,134 (34.0) | |
51–60 | 1,908 (29.3) | 941 (29.6) | 967 (29.0) | |
61–70 | 1,120 (17.2) | 548 (17.2) | 572 (17.2) | |
> 70 | 501 (7.7) | 227 (7.1) | 274 (8.2) | |
Sex | ||||
Male | 12 (0.2) | 7 (0.2) | 5 (0.1) | 0.573 |
Female | 6,502 (99.8) | 3,175 (99.8) | 3,327 (99.9) | |
Detection of cancer | ||||
Screening | 3,452 (53.0) | 1,638 (51.5) | 1,814 (54.4) | < 0.001 |
Symptomatic | 2,922 (44.9) | 1,490 (46.8) | 1,432 (43.0) | |
Unknown | 140 (2.1) | 54 (1.7) | 86 (2.6) | |
T category (unknown=48) | ||||
0 | 30 (0.5) | 24 (0.7) | 6 (0.2) | 0.002 |
1 | 3,587 (55.5) | 1,703 (54.1) | 1,884 (56.8) | |
2 | 2,341 (36.2) | 1,161 (36.9) | 1,180 (35.6) | |
3 | 343 (5.3) | 173 (5.5) | 170 (5.1) | |
4 | 165 (2.5) | 88 (2.8) | 77 (2.3) | |
N category (unknown=42) | ||||
0 | 3,968 (61.3) | 1,889 (59.9) | 2,079 (62.7) | 0.071 |
1 | 1,627 (25.1) | 821 (26.0) | 806 (24.3) | |
2 | 510 (7.9) | 259 (8.2) | 251 (7.6) | |
3 | 329 (5.1) | 172 (5.5) | 157 (4.7) | |
4 | 38 (0.6) | 14 (0.4) | 24 (0.7) | |
Stage | ||||
I | 3,041 (46.7) | 1,440 (45.2) | 1,601 (48.1) | 0.001 |
II | 2,405 (36.9) | 1,178 (37.0) | 1,227 (36.8) | |
III | 964 (14.8) | 495 (15.6) | 469 (14.1) | |
IV | 104 (1.6) | 69 (2.2) | 35 (1.0) | |
Subtypes (unknown=60) | ||||
HR+/HER2− | 4,122 (63.9) | 2,005 (63.5) | 2,117 (64.2) | 0.452 |
HR+/HER2+ | 636 (9.8) | 298 (9.4) | 338 (10.3) | |
HR−/HER2+ | 714 (11.1) | 358 (11.4) | 356 (10.8) | |
HR−/HER2− | 982 (15.2) | 496 (15.7) | 486 (14.7) |
Values are presented as number (%) unless otherwise indicated. COVID-19, coronavirus disease 2019; HER2, human epidermal growth factor receptor 2; HR, hormonal receptor; N, node; SD, standard deviation; T, tumor.
a)t test,
b)Chi-squared test,
c)Fisher’s exact test.
Characteristic | Total (n=6,514) | Pre–COVID-19 (2019) (n=3,182) | COVID-19 (≥ 2020) (n=3,332) | p-value |
---|---|---|---|---|
Type of first treatment | ||||
Surgery | 4,820 (74.0) | 2,279 (71.6) | 2,541 (76.3) | < 0.001 |
Chemotherapy | 1,639 (25.2) | 867 (27.3) | 772 (23.2) | |
Hormone therapy | 54 (0.8) | 36 (1.1) | 18 (0.5) | |
Radiation therapy | 1 (0.0) | 0 | 1 (0.0) | |
Surgery as first treatment (n=4,820) | ||||
Surgery type | ||||
BCS | 3,415 (70.9) | 1,561 (68.5) | 1,854 (73.0) | 0.001 |
Mastectomy | 1,400 (29.0) | 714 (31.3) | 686 (27.0) | |
Axillary only | 5 (0.1) | 4 (0.2) | 1 (0.0) | |
Chemotherapy as first treatment (n=1,639) | ||||
Chemotherapy | ||||
Neoadjuvant | 1,592 (97.1) | 838 (96.7) | 754 (97.7) | 0.220 |
Palliative | 47 (2.9) | 29 (3.3) | 18 (2.3) | |
Time duration from diagnosis to first treatment (day) | ||||
Median (min-max) | 36 (0–348) | 37 (0–348) | 35 (0–280) | 0.001 |
Values are presented as number (%) unless otherwise indicated. BCS, breast conserving surgery; COVID-19, coronavirus disease 2019.
a)Fisher’s exact test,
b)Wilcoxon rank sum test.
Characteristic | Hospital 1 |
Hospital 2 |
Hospital 3 | ||||||
---|---|---|---|---|---|---|---|---|---|
Pre–COVID-19 (2019) (n=1,399) | COVID-19 (≥ 2020) (n=1,596) | p-value | Pre–COVID-19 (2019) (n=833) | COVID-19 (≥ 2020) (n=900) | p-value | Pre–COVID-19 (2019) (n=925) | COVID-19 (≥ 2020) (n=861) | p-value | |
Age (yr) | |||||||||
Mean±SD | 52.7±10.8 | 52.7±11.1 | 0.981 |
53.6±10.9 | 54.8±11.2 | 0.020 |
53.0±11.1 | 53.3±11.8 | 0.649 |
Median (min-max) | 52 (23–87) | 51 (20–86) | 52 (30–88) | 53 (29–91) | 51 (26–85) | 51 (22–89) | |||
Age group (yr) | |||||||||
≤ 40 | 169 (12.1) | 208 (13.0) | 0.652 |
83 (10.0) | 70 (7.8) | 0.060 |
108 (11.4) | 107 (12.8) | 0.523 |
41–65 | 1,061 (75.8) | 1,188 (74.4) | 634 (76.1) | 674 (74.9) | 698 (73.5) | 595 (71.2) | |||
> 65 | 169 (12.1) | 200 (12.6) | 116 (13.9) | 156 (17.3) | 144 (15.1) | 134 (16.0) | |||
Age group (yr) | |||||||||
≤ 40 | 169 (12.1) | 208 (13.0) | 0.783 |
83 (10.0) | 70 (7.8) | 0.310 |
108 (11.4) | 107 (12.8) | 0.348 |
41–50 | 466 (33.3) | 535 (33.5) | 294 (35.3) | 296 (32.9) | 346 (36.4) | 303 (36.2) | |||
51–60 | 435 (31.1) | 476 (29.9) | 245 (29.4) | 287 (31.9) | 261 (27.5) | 204 (24.4) | |||
61–70 | 248 (17.7) | 273 (17.1) | 139 (16.7) | 159 (17.6) | 161 (16.9) | 140 (16.8) | |||
> 70 | 81 (5.8) | 104 (6.5) | 72 (8.6) | 88 (9.8) | 74 (7.8) | 82 (9.8) | |||
Detection of cancer | |||||||||
Screening | 1,051 (75.1) | 1,213 (76.0) | 0.049 |
184 (22.1) | 239 (26.6) | 0.031 |
403 (42.4) | 362 (43.3) | 0.004 |
Symptomatic | 348 (24.9) | 377 (23.6) | 649 (77.9) | 661 (73.4) | 493 (51.9) | 394 (47.1) | |||
Unknown | 0 | 6 (0.4) | 54 (5.7) | 80 (9.6) | |||||
Stage | |||||||||
I | 583 (41.7) | 703 (44.0) | 0.073 |
378 (45.4) | 465 (51.7) | < 0.001 |
479 (50.4) | 433 (51.8) | 0.119 |
II | 541 (38.7) | 616 (38.6) | 288 (34.6) | 327 (36.3) | 349 (36.7) | 284 (34.0) | |||
III | 256 (18.3) | 268 (16.8) | 129 (15.5) | 86 (9.6) | 110 (11.6) | 115 (13.7) | |||
IV | 19 (1.3) | 9 (0.6) | 38 (4.5) | 22 (2.4) | 12 (1.3) | 4 (0.5) | |||
T category (unknown=46) | |||||||||
0 | 7 (0.5) | 3 (0.2) | 0.058 |
6 (0.7) | 2 (0.2) | 0.001 |
11 (1.2) | 1 (0.1) | 0.012 |
1 | 686 (49.0) | 831 (52.1) | 438 (54.8) | 538 (60.8) | 579 (60.9) | 515 (61.6) | |||
2 | 565 (40.4) | 605 (37.9) | 280 (35.0) | 304 (34.4) | 316 (33.3) | 271 (32.4) | |||
3 | 72 (5.2) | 99 (6.2) | 59 (7.4) | 31 (3.5) | 42 (4.4) | 40 (4.8) | |||
4 | 69 (4.9) | 58 (3.6) | 17 (2.1) | 10 (1.1) | 2 (0.2) | 9 (1.1) | |||
N category (unknown=42) | |||||||||
0 | 824 (58.9) | 964 (60.4) | 0.521 |
448 (55.6) | 572 (64.7) | < 0.001 |
617 (65.0) | 543 (64.9) | 0.931 |
1 | 346 (24.7) | 396 (24.8) | 256 (31.8) | 225 (25.4) | 219 (23.0) | 185 (22.1) | |||
2 | 151 (10.8) | 153 (9.6) | 42 (5.2) | 39 (4.4) | 66 (7.0) | 59 (7.1) | |||
3 | 77 (5.5) | 79 (5.0) | 52 (6.4) | 33 (3.7) | 43 (4.5) | 45 (5.4) | |||
4 | 1 (0.1) | 4 (0.2) | 8 (1.0) | 16 (1.8) | 5 (0.5) | 4 (0.5) | |||
Subtypes (unknown=60) | |||||||||
HR+/HER2− | 852 (62.0) | 996 (63.7) | 0.048 |
532 (63.9) | 569 (63.4) | 0.974 |
621 (65.4) | 552 (66.0) | 0.979 |
HR+/HER2+ | 123 (9.0) | 174 (11.1) | 82 (9.8) | 87 (9.7) | 93 (9.8) | 77 (9.2) | |||
HR−/HER2+ | 151 (10.9) | 149 (9.6) | 96 (11.5) | 110 (12.2) | 111 (11.7) | 97 (11.6) | |||
HR−/HER2− | 248 (18.1) | 244 (15.6) | 123 (14.8) | 132 (14.7) | 125 (13.1) | 110 (13.2) | |||
Type of first treatment | |||||||||
Surgery | 1,006 (71.9) | 1,129 (70.7) | 0.654 |
540 (64.8) | 729 (81.0) | < 0.001 |
733 (77.2) | 683 (81.7) | 0.038 |
Chemotherapy | 387 (27.7) | 462 (29.0) | 269 (32.3) | 159 (17.7) | 211 (22.2) | 151 (18.1) | |||
Hormone therapy | 6 (0.4) | 5 (0.3) | 24 (2.9) | 11 (1.2) | 6 (0.6) | 2 (0.2) | |||
Radiation therapy | 0 | 1 (0.1) | |||||||
Surgery as first treatment | |||||||||
Surgery type | |||||||||
BCS | 619 (61.5) | 695 (61.6) | > 0.99 |
465 (86.1) | 642 (88.1) | 0.282 |
477 (65.1) | 517 (75.7) | < 0.001 |
Mastectomy | 386 (38.4) | 433 (38.3) | 74 (13.7) | 87 (11.9) | 254 (34.6) | 166 (24.3) | |||
Axillary only | 1 (0.1) | 1 (0.1) | 1 (0.2) | 0 | 2 (0.3) | 0 | |||
Chemotherapy as first treatment | |||||||||
Chemotherapy | |||||||||
Neoadjuvant | 376 (97.2) | 457 (98.9) | 0.060 |
252 (93.7) | 147 (92.5) | 0.625 |
210 (99.5) | 150 (99.3) | > 0.99 |
Palliative | 11 (2.8) | 5 (1.1) | 17 (6.3) | 12 (7.5) | 1 (0.5) | 1 (0.7) | |||
Time duration from diagnosis to first treatment (day) | |||||||||
Median (min-max) | 46 (0–348) | 41 (0–280) | < 0.000 |
37 (0–170) | 35 (0–117) | 0.013 |
28 (0–311) | 28 (0–117) | 0.866 |
Values are presented as number (%) unless otherwise indicated. BCS, breast conserving surgery; COVID-19, coronavirus disease 2019; HER2, human epidermal growth factor receptor 2; HR, hormonal receptor; N, node; SD, standard deviation; T, tumor.
a)t test,
b)Chi-squared test,
c)Fisher’s exact test,
d)Wilcoxon rank sum test.
Values are presented as number (%) unless otherwise indicated. COVID-19, coronavirus disease 2019; HER2, human epidermal growth factor receptor 2; HR, hormonal receptor; N, node; SD, standard deviation; T, tumor. t test, Chi-squared test, Fisher’s exact test.
Values are presented as number (%) unless otherwise indicated. BCS, breast conserving surgery; COVID-19, coronavirus disease 2019. Fisher’s exact test, Wilcoxon rank sum test.
Values are presented as number (%) unless otherwise indicated. BCS, breast conserving surgery; COVID-19, coronavirus disease 2019; HER2, human epidermal growth factor receptor 2; HR, hormonal receptor; N, node; SD, standard deviation; T, tumor. t test, Chi-squared test, Fisher’s exact test, Wilcoxon rank sum test.